Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: Comparison of BCLC, TNM and Hangzhou criteria staging systems

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Liu, Chang ^a   Duan, Li Gen ^a   Lu, Wu Sheng ^a   Yan, Lu Nan ^a   Xiao, Guang Qin ^a   Jiang, Li ^a   Yang, Jian ^a   Yang, Jiayin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AKAIKE INFORMATION CRITERION; AREA UNDER THE CURVE; ARTICLE; C INDEX; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHINESE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HANGZHOU CRITERIA; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PORTAL VEIN; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TUMOR INVASION; UNIVARIATE ANALYSIS; VERY ELDERLY; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 84926334599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103228     Document Type: Article

References (36)

1. Jiang X, Pan SY, de Groh M, Liu S, Morrison H (2011) Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis. J Gastrointest Oncol 2: 223-231.
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750. (Pubitemid 29114292)
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
4. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, et al. (2006) The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43: 1303-1310. (Pubitemid 43980109)
5. Wild CP, Hall AJ (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462: 381-393. (Pubitemid 30190243)
6. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
7. Lu W, Dong J, Huang Z, Guo D, Liu Y, et al. (2008) Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 23: 1874-1878.
8. Poon RT, Fan ST (2003) Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 12: 35-50, viii. (Pubitemid 36204978)
9. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474.
10. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
11. Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30: 61-74.
12. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707-716. (Pubitemid 40462931)
13. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, et al. (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44: 723-731.
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430. (Pubitemid 32844200)
15. Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, et al. (2008) Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 103: 597-604. (Pubitemid 351405970)
16. Zheng SS, Xu X, Wu J, Chen J, Wang WL, et al. (2008) Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 85: 1726-1732.
17. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699. (Pubitemid 26079803)
18. Seo YS, Kim YJ, Um SH, Yoo H, Lee JW, et al. (2008) Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 23: 1267-1275.
19. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, et al. (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34: 529-534. (Pubitemid 32786644)
20. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, et al. (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418. (Pubitemid 40299100)
21. De Carlis L, Giacomoni A, Pirotta V, Lauterio A, Slim AO, et al. (2003) Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 196: 887-897. (Pubitemid 36676550)
22. Faber W, Sharafi S, Stockmann M, Denecke T, Sinn B, et al. (2012) Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery.
23. Skolnick AA (1996) Armed with epidemiologic research, China launches programs to prevent liver cancer. JAMA 276: 1458-1459.
24. Yuen MF, Hou JL, Chutaputti A (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24: 346-353.
25. Li Q, Li H, Qin Y, Wang PP, Hao X (2007) Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. J Gastroenterol Hepatol 22: 1936-1941. (Pubitemid 47525057)
26. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, et al. (2001) Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 48: 103-109. (Pubitemid 32042649)
27. Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, et al. (2011) A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol 137: 739-750.
28. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127.
29. Sirivatanauksorn Y, Tovikkai C (2011) Comparison of staging systems of hepatocellular carcinoma. HPB Surg 2011: 818217.
30. Lei J, Yan L (2013) Outcome Comparisons Among the Hangzhou, Chengdu, and UCSF Criteria for Hepatocellular Carcinoma Liver Transplantation after Successful Downstaging Therapies. J Gastrointest Surg.
31. Zhou J, Yan T, Bi X, Zhao H, Huang Z, et al. (2013) Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. Tumour Biol 34: 1061-1070.
32. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, et al. (2008) The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer 44: 1000-1006.
33. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, et al. (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134: 1908-1916. (Pubitemid 351783260)
34. Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, et al. (2008) Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg 143: 1082-1090.
35. Taketa K (1990) Alpha-fetoprotein: reevaluation in hepatology. Hepatology 12: 1420-1432.
36. Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, et al. (2010) Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein. Liver Int 30: 1161-1168.